FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:280-282 January 24, 2002 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Coiffier, B. PubMed Citation

Research on the treatment of the non-Hodgkin's lymphomas has finally emerged from decades of stagnation. These lymphomas, which usually arise from B lymphocytes, are the fifth most common type of cancer in the United States and are the fifth and sixth leading cause of death from cancer in men and women, respectively.¹ Approximately 25 to 30 percent of non-Hodgkin's lymphomas have an indolent course; the remainder are aggressive tumors. For 25 years, the standard treatment for diffuse large-B-cell lymphoma, the most common of the aggressive non-Hodgkin's lymphomas, has been a regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), which cures . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Huber, L C, Kunzler, P, Boyce, S H, Michel, B A, Gay, R E, Ink, B S, Gay, S (2008). Effects of a novel tyrosine kinase inhibitor in rheumatoid arthritis synovial fibroblasts. Ann Rheum Dis 67: 389-394 [Abstract] [Full Text]  
• Fillet, G., Bonnet, C. (2007). In Reply. JCO 25: 2857-2858 [Full Text]  
• Huber, L. C., Distler, O., Tarner, I., Gay, R. E., Gay, S., Pap, T. (2006). Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford) 45: 669-675 [Abstract] [Full Text]  
• Leonard, J. P., Coleman, M., Ketas, J., Ashe, M., Fiore, J. M., Furman, R. R., Niesvizky, R., Shore, T., Chadburn, A., Horne, H., Kovacs, J., Ding, C. L., Wegener, W. A., Horak, I. D., Goldenberg, D. M. (2005). Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma. JCO 23: 5044-5051 [Abstract] [Full Text]  
• Dupuy, A., Viguier, M., Bedane, C., Cordoliani, F., Blaise, S., Aucouturier, F., Bonnetblanc, J.-M., Morel, P., Dubertret, L., Bachelez, H. (2004). Treatment of Refractory Pemphigus Vulgaris With Rituximab (Anti-CD20 Monoclonal Antibody). Arch Dermatol 140: 91-96 [Abstract] [Full Text]  
• Sansonno, D., De Re, V., Lauletta, G., Tucci, F. A., Boiocchi, M., Dammacco, F. (2003). Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101: 3818-3826 [Abstract] [Full Text]